These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22258112)

  • 1. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database.
    Confavreux CB; Canoui-Poitrine F; Schott AM; Ambrosi V; Tainturier V; Chapurlat RD
    Eur J Endocrinol; 2012 Apr; 166(4):735-41. PubMed ID: 22258112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
    Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
    Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
    Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
    Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
    Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
    Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
    Li L; Roddam A; Gitlin M; Taylor A; Shepherd S; Shearer A; Jick S
    Menopause; 2012 Jan; 19(1):33-40. PubMed ID: 21926926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
    Jacob L; Dreher M; Kostev K; Hadji P
    Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday.
    Eliasaf A; Amitai A; Maram Edry M; Yosselson Superstine S; Rotman Pikielny P
    J Clin Pharmacol; 2016 Nov; 56(11):1416-1422. PubMed ID: 26999526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database.
    Li L; Roddam A; Ferguson S; Feudjo-Tepie M; Taylor A; Jick S
    Menopause; 2014 Oct; 21(10):1106-13. PubMed ID: 24569621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving adherence to and persistence with oral therapy of osteoporosis.
    Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
    Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.